Piramal OTC aims to double turnover to Rs 1,000 cr in three years

PEL's Pharma and financial services arms demerger is expected to be completed over next 3 quarters

The Nandini Piramal-led over-the-counter (OTC) healthcare business of Piramal Enterprises is not only aiming to double its turnover to Rs 1,000 crore in three years, but now aims to focus more on building a consumer pull for its brands.

Last month Piramal Enterprises (PEL) said that it would demerge its pharma and financial services arm. The demerger is expected to be completed over the next three quarters.

Piramal Pharma, however, draws only 15 per cent of its Rs 5,776 crore revenues from the India business, and bulk comes from North America.

Piramal’s pharma business comprises a contract development and manufacturing